Obinutuzumab for adults with rituximab-dependent nephrotic syndrome
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called obinutuzumab to see if it can keep nephrotic syndrome from coming back in adults who need repeated rituximab treatments. The goal is to see if obinutuzumab works better at controlling the disease compared to current care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a kidney biopsy from the last 5 years showing minimal change disease, focal segmental glomerulosclerosis, or IgM nephropathy.
- Your nephrotic syndrome must have come back within 12 months after stopping rituximab treatment (with high protein in urine and low albumin in blood).
- Your kidney function (eGFR) must be at least 30 ml/min/1.73 m².
- You must be willing to use effective birth control during the study and for 18 months after, if you could have children.
- You cannot have recent cancer (within 5 years), active infections, severe heart failure, or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This trial tests a new medicine called O-triple for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if it can control the disease and help protect kidney function.
Hear when a new Nephrotic Syndrome，Idiopathic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.